JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cleare, W.
Right arrow Articles by Casadevall, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cleare, W.
Right arrow Articles by Casadevall, A.

Journal of Clinical Microbiology, September 1999, p. 3080-3080, Vol. 37, No. 9
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

LETTERS TO THE EDITOR

Monoclonal Antibody 13F1 Produces Annular Immunofluorescence Patterns on Cryptococcus neoformans Serotype AD Isolates


    LETTER
Top
Letter
References

Cryptococcus neoformans isolates have been grouped serologically into five serotypes known as A, D, AD, B, and C. Recently, a proposal to separate serotype A and D isolates into two varieties, known as grubii and neoformans, respectively, was made (4). Of the five serotypes, the AD type is probably the least studied. Restriction fragment length polymorphism, multilocus enzyme electrophoresis, and random amplified polymorphic DNA analyses reveal that AD isolates comprise a discrete group that can be distinguished from both serotypes A and D (2, 7, 9).

Monoclonal antibody (MAb) 13F1 is a murine immunoglobulin M (IgM) that binds to the capsular glucuronoxylomannan (3). Indirect immunofluorescence (IF) staining of serotype A and D strains produces annular and punctate patterns, respectively (3, 8). Differences in MAb 13F1 IF binding have been used to support the proposal to separate these serotypes into two varieties (4). In the present study, we investigated the IF pattern of MAb 13F1 for 12 serotype AD isolates which had been collected from Atlanta, Ga.; San Francisco, Calif.; Houston, Tex.; and the state of Alabama as part of the Centers for Disease Control and Prevention cryptococcal active surveillance project (1). IF was done as described elsewhere (3).

All isolates produced annular IF with MAb 12A1, showing that this IgM does not discriminate among serotypes A, D, and AD. In contrast, MAb 13F1 produced a qualitatively different IF pattern only with serotype D isolates. Of 15 AD isolates, all except one produced annular IF patterns with MAb 13F1. For this isolate there was a mixed IF pattern. These results show that MAb 13F1 IF patterns do not discriminate between the A and AD serotypes. The finding that MAb 13F1 binding to AD isolates produced annular IF provides additional support for the conclusion that the punctate IF pattern with MAb 13F1 is highly predictive of serotype D classification (3). The production of a punctate IF pattern with MAb 13F1 has been proposed as a characteristic distinguishing between the varieties grubii and neoformans (4). The finding that MAb 13F1 discriminates between serotypes AD and D supports its usefulness in identifying variety neoformans (serotype D) isolates. The specificity of MAb 13F1 is different from that of the serotype D-specific MAb CRND-8 described by Ikeda et al., which reacted with serotypes D and AD but not serotype A (6). Chemical analysis of the capsular polysaccharide of serotype AD strains shows that it is very similar to that of serotypes A and D but differs primarily in the ratio of substituted to unsubstituted mannose residues (5). The finding of Ikeda et al. that MAb CRND-8 discriminated between serotypes AD and A (6) combined with our finding that MAb 13F1 discriminates between AD and D provides support for the proposal that AD does represents a fifth C. neoformans serotype.


    FOOTNOTES

* Phone: (718) 430-4259

Fax: (718) 430-8968

E-mail: casadeva{at}aecom.yu.edu


    REFERENCES
Top
Letter
References

1. Brandt, M., L. C. Hutwagner, L. A. Klug, W. S. Baughman, D. Rimland, E. A. Graviss, R. J. Hamill, C. Thomas, P. G. Pappas, A. L. Reingold, and R. W. Pinner. 1996. Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. J. Clin. Microbiol. 34:912-917[Abstract].
2. Brandt, M. E., L. C. Hutwagner, R. J. Kuykendall, R. W. Pinner, and The Cryptococcal Disease Active Surveillance Group. 1995. Comparison of multilocus enzyme electrophoresis and random amplified polymorphic DNA analysis for molecular subtyping of Cryptococcus neoformans. J. Clin. Microbiol. 33:1890-1895[Abstract].
3. Cleare, W., and A. Casadevall. 1998. The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays. Clin. Diagn. Lab. Immunol. 5:125-129[Abstract/Free Full Text].
4. Franzot, S. P., I. F. Salkin, and A. Casadevall. 1999. Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J. Clin. Microbiol. 37:838-840[Abstract/Free Full Text].
5. Ikeda, R., H. Matsuyama, A. Nishikawa, T. Shinoda, and Y. Fukazawa. 1991. Comparison of serological and chemical characteristics of capsular polysaccharides of Cryptococcus neoformans var. neoformans serotype A and Cryptococcus albidus var. albidus. Microbiol. Immunol. 35:125-138[Medline].
6. Ikeda, R., S. Nishimura, A. Nishikawa, and T. Shinoda. 1996. Production of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D. Clin. Diagn. Lab. Immunol. 3:89-92[Abstract].
7. Kohno, S., A. Varma, K. J. Kwon-Chung, and K. Hara. 1994. Epidemiology studies of clinical isolates of Cryptococcus neoformans of Japan by restriction fragment length polymorphism. J. Jpn. Assoc. Infect. Dis. 68:1512-1517.
8. Nussbaum, G., W. Cleare, A. Casadevall, M. D. Scharff, and P. Valadon. 1997. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J. Exp. Med. 185:685-697[Abstract/Free Full Text].
9. Viviani, M. A., H. Wen, A. Roverselli, R. Caldarelli-Stefano, M. Cogliati, P. Ferrante, and A. M. Tortorano. 1997. Identification by polymerase chain reaction fingerprinting of Cryptococcus neoformans serotype AD. J. Med. Vet. Mycol. 35:355-360[Medline].
Wendy Cleare
Department of Microbiology and Immunology
Albert Einstein College of Medicine
1300 Morris Park Ave.
Bronx, New York 10461
Mary E. Brandt
Mycotic Diseases Branch
National Center for Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, Georgia 30333
Arturo Casadevall*
Department of Medicine
Albert Einstein College of Medicine
1300 Morris Park Ave.
Bronx, New York 10461


Journal of Clinical Microbiology, September 1999, p. 3080-3080, Vol. 37, No. 9
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cleare, W.
Right arrow Articles by Casadevall, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cleare, W.
Right arrow Articles by Casadevall, A.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS